GLO1 - A novel amplified gene in human cancer

Genes Chromosomes and Cancer

Volumn 49, Issue 8, 2010, Pages 711-725

  Santarius, Thomas ^a,b   Bignell, Graham R ^a   Greenman, Chris D ^a   Widaa, Sara ^a   Chen, Lina ^a   Mahoney, Claire L ^a   Butler, Adam ^a   Edkins, Sarah ^a   Waris, Sahar ^c   Thornalley, Paul J ^c   Futreal, P Andrew ^a   Stratton, Michael R ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYOXALASE; GLYOXALASE 1; UNCLASSIFIED DRUG;

AMPLICON; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CHROMOSOME 6P; COLON CANCER; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC SCREENING; GLIOMA; HUMAN; HUMAN CELL; KIDNEY CANCER; KNOCKOUT GENE; LUNG NON SMALL CELL CANCER; NEOPLASM; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TUMOR GENE;

APOPTOSIS; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 6; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; LACTOYLGLUTATHIONE LYASE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 77953513144     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20784     Document Type: Article

References (31)

1. Albertson DG. 2006. Gene amplification in cancer. Trends Genet 22:447-455.
2. Bignell GR, Huang J, Greshock J, Watt S, Butler A, West S, Grigorova M, Jones KW, Wei W, Stratton MR, Futreal PA, Weber B, Shapero MH, Wooster R. 2004. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res 14:287-295.
3. Bignell GR, Santarius T, Pole JC, Butler AP, Perry J, Pleasance E, Greenman C, Menzies A, Taylor S, Edkins S, Campbell P, Quail M, Plumb B, Matthews L, McLay K, Edwards PA, Rogers J, Wooster R, Futreal PA, Stratton MR. 2007. Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res 17:1296-1303.
4. Bolstad BM, Irizarry RA, Astrand M, Speed TP. 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193. (Pubitemid 36181903)
5. Davidson SD, Cherry JP, Choudhury MS, Tazaki H, Mallouh C, Konno S. 1999. Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy. J Urol 161:690-691.
6. Davies GF, Roesler WJ, Juurlink BH, Harkness TA. 2005a. Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leuk Lymphoma 46:1199-1206.
7. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, Parker A, O'Meara S, Avis T, Barthorpe S, Brackenbury L, Buck G, Clements J, Cole J, Dicks E, Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Shepherd R, Small A, Solomon H, Stephens Y, Tofts C, Varian J, Webb A, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LH, Malkowicz B, Pierotti MA, Teh BT, Yuen ST, Lakhani SR, Easton DF, Weber BL, Goldstraw P, Nicholson AG, Wooster R, Stratton MR, Futreal PA. 2005b. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65:7591-7595.
8. Davies H, Dicks E, Stephens P, Cox C, Teague J, Greenman C, Bignell G, O'Meara S, Edkins S, Parker A, Stevens C, Menzies A, Blow M, Bottomley B, Dronsfield M, Futreal PA, Stratton MR, Wooster R. 2006. High throughput DNA sequence variant detection by conformation sensitive capillary electrophoresis and automated peak comparison. Genomics 87:427-432.
9. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. 2004. A census of human cancer genes. Nat Rev Cancer 4:177-183.
10. Gautier L, Cope L, Bolstad BM, Irizarry RA. 2004. affy - Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20:307-315. (Pubitemid 38262761)
11. Greenman C, Bignell GR, Butler A, Edkins S, Hinton J, Beare DM, Swamy S, Santarius T, Chen L, Widaa S, Futreal PA, Stratton MR. 2010. PICNIC: An algorithm to predict absolute allelic copy number variation with microarray cancer data. Biostatistics 11:164-175.
12. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. 2003a. Summaries of affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15.
13. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003b. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264.
14. Kerbel RS. 2008. Tumor angiogenesis. N Engl J Med 358:2039-2049.
15. Lo TW, Thornalley PJ. 1993. Inhibition of human leukaemia 60 cell growth by diethyl esterification of the glyoxalase II inhibitor S-p- nitrobenzoxycarbonylglutathione in vitro. Biochem Soc Trans 21:159S.
16. Myllykangas S, Knuutila S. 2006. Manifestation, mechanisms and mysteries of gene amplifications. Cancer Lett 232:79-89. (Pubitemid 43053935)
17. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, Seto M. 2004. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64:3087-3095. (Pubitemid 38581408)
18. Ovcharenko D, Jarvis R, Hunicke-Smith S, Kelnar K, Brown D. 2005. High-throughput RNAi screening in vitro: From cell lines to primary cells. RNA 11:985-993. (Pubitemid 40994209)
19. Pfaffl MW, Horgan GW, Dempfle L. 2002. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36.
20. Ranganathan S, Walsh ES, Godwin AK, Tew KD. 1993. Cloning and characterization of human colon glyoxalase-I. J Biol Chem 268:5661-5667. (Pubitemid 23090890)
21. Ranganathan S, Walsh ES, Tew KD. 1995. Glyoxalase I in detoxification: Studies using a glyoxalase I transfectant cell line. Biochem J 309 (Part 1):127-131.
22. Rozen S, Skaletsky H. 2000. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, editors. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa: Humana Press.
23. Rulli A, Carli L, Romani R, Baroni T, Giovannini E, Rosi G, Talesa V. 2001. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res Treat 66:67-72.
24. Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, Tsuruo T. 2000. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 95:3214-3218.
25. Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T. 2001. Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res 7:2513-2518.
26. Schwab M. 1998. Amplification of oncogenes in human cancer cells. Bioessays 20:473-479.
27. Schwab M. 1999. Oncogene amplification in solid tumors. Semin Cancer Biol 9:319-325.
28. Thornalley PJ. 1996. Pharmacology of methylglyoxal: Formation, modification of proteins and nucleic acids, and enzymatic detoxification - A role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 27:565-573.
29. Thornalley PJ. 2003. Protecting the genome: Defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochem Soc Trans 31:1372-1377.
30. Thornalley PJ, Edwards LG, Kang Y, Wyatt C, Davies N, Ladan MJ, Double J. 1996. Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochem Pharmacol 51:1365-1372.
31. Wlodarska I, Dierickx D, Vanhentenrijk V, Van RK, Pospisilova H, Minnei F, Verhoef G, Thomas J, Vandenberghe P, De Wolf-Peeters C. 2008. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 111:5683-5690.